Stock Research for MD

Featured Broker: Ally Invest

Get the due diligence for another stock.


MD Stock Chart & Research Data

The MD chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the MD chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


MD Due diligence Resources & Stock Charts

The MD stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View MD Detailed Price Forecast - CNN Money CNN View MD Detailed Summary - Google Finance
Yahoo View MD Detailed Summary - Yahoo! Finance Zacks View MD Stock Research & Analysis -

Stock Analysis

TradeIdeas View MD Trends & Analysis - Trade-Ideas Barrons View MD Major Holders - Barrons
NASDAQ View MD Call Transcripts - NASDAQ Seeking View MD Breaking News & Analysis - Seeking Alpha
Spotlight View MD Annual Report - OTC Report View MD OTC Short Report -
TradeKing View MD Fundamentals - TradeKing Charts View MD SEC Filings - Bar Chart
WSJ View Historical Prices for MD - The WSJ Morningstar View Performance/Total Return for MD - Morningstar
MarketWatch View the Analyst Estimates for MD - MarketWatch CNBC View the Earnings History for MD - CNBC
StockMarketWatch View the MD Earnings - StockMarketWatch MacroAxis View MD Buy or Sell Recommendations - MacroAxis
Bullish View the MD Bullish Patterns - American Bulls Short Pains View MD Short Pain Metrics -

Social Media Mentions

StockTwits View MD Stock Mentions - StockTwits PennyStocks View MD Stock Mentions - PennyStockTweets
Twitter View MD Stock Mentions - Twitter Invest Hub View MD Investment Forum News - Investor Hub
Yahoo View MD Stock Mentions - Yahoo! Message Board Seeking Alpha View MD Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for MD - Insider Cow View Insider Transactions for MD - Insider Cow
CNBC View MD Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for MD - OTC Markets
Yahoo View Insider Transactions for MD - Yahoo! Finance NASDAQ View Institutional Holdings for MD - NASDAQ

Stock Charts

FinViz View MD Stock Insight & Charts - StockCharts View MD Investment Charts -
BarChart View MD Stock Overview & Charts - BarChart Trading View View MD User Generated Charts - Trading View

Latest Financial News for MD

Mighty Elliott Associates’ Failed Mednax Inc. (NYSE:MD) Activist Campaign
Posted on Friday September 21, 2018

Paul Singer’s Elliott Associates built a reputation as one of the fiercest activist hedge funds in the investment world. You can easily find an article about this fund by a major media company every week. Paul Singer doesn’t have any problem raising capital whenever he wants to. Yet, we aren’t impressed by its performance at all. […]

3 Top Healthcare Stocks to Buy Right Now
Posted on Tuesday September 18, 2018

A large-cap big pharma, a mid-cap specialized care provider, and a small-cap biotech stand out as great healthcare stocks.

DaVita’s Quarterly Revenue Trend
Posted on Monday September 17, 2018

DaVita (DVA) reported revenues of ~$2.9 billion in the second quarter of 2018, which is a 6.9% YoY (year-over-year) growth compared to $2.7 billion in the second quarter of 2017. DaVita reported 6.9% growth in its top line to $2.89 billion, including an 11.1% growth in revenues from US dialysis and related lab services to $2.57 billion, offset by a 17.7% decrease in revenues for other ancillary services and strategic initiatives in the second quarter of 2018. Medicare and Medicare Advantage revenues were $1.5 billion in the second quarter of 2018, a 16.2% growth compared to $1.3 billion in the second quarter of 2017.

DaVita’s Valuation on September 17
Posted on Monday September 17, 2018

DaVita (DVA) is a biotechnology company focused on the discovery, development, and commercialization of specialist medicines to cater to the medical needs in rare diseases and other specialized conditions. DaVita reported non-GAAP EPS of $1.15 on revenues of $2.9 billion, a 6.9% growth YoY (year-over-year) compared to $2.7 billion in the second quarter of 2017.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.